[Soft tissue sarcoma: prognostic factors and multimodal treatment]

Area of Science:

• Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Soft-tissue sarcomas are rare adult malignancies, comprising about 1% of all cancers.
• These tumors exhibit diverse histological subtypes but share similar biological behaviors and treatment responses.
• They commonly affect the extremities (up to 50%), followed by visceral/retroperitoneal and trunk locations.

Purpose of the Study:

• To review the primary therapy, recurrence patterns, and treatment outcomes for soft-tissue sarcomas.
• To highlight the importance of surgical resection and adjuvant therapies for local control.
• To discuss management strategies for recurrent and metastatic disease.

Main Methods:

• Review of existing literature on soft-tissue sarcoma treatment and outcomes.
• Analysis of recurrence rates based on tumor location and risk factors.
• Evaluation of treatment efficacy for primary, recurrent, and metastatic disease.

Main Results:

• Primary treatment involves surgical resection with adequate margins; limb-sparing surgery is feasible in over 90% of extremity cases.
• Adjuvant radiation improves local control for high-risk patients (based on grade, size, site).
• Local recurrence rates vary (e.g., one-third for extremity lesions, 40-50% for visceral sarcomas), but recurrences can be treated effectively.
• Pulmonary metastases can be resected with 20-30% 3-year survival; unresectable or extra-pulmonary metastases have a poor prognosis, managed with chemotherapy.

Conclusions:

• Optimal soft-tissue sarcoma management requires individualized treatment plans.
• Surgical resection remains the cornerstone of therapy, with adjuvant radiation improving local control in high-risk cases.
• Effective management of recurrences and metastases is crucial, with systemic chemotherapy indicated for advanced disease.